A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOV (Q38470620)
Jump to navigation
Jump to search
scientific article published on 29 May 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOV |
scientific article published on 29 May 2012 |
Statements
1 reference
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOV (English)
1 reference
1 reference
Robert A Harrington
1 reference
Deepak L Bhatt
1 reference
Janusz Kochman
1 reference
Paul A Gurbel
1 reference
Dominick J Angiolillo
1 reference
Sunil V Rao
1 reference
Uwe Zeymer
1 reference
Vivian P Thompson
1 reference
Kurt Huber
1 reference
Matthew W McClure
1 reference
Daniel D Gretler
1 reference
C Michael Gibson
1 reference
Lisa G Berdan
1 reference
Gayle Paynter
1 reference
Sergio Leonardi
1 reference
Mina Madan
1 reference
William J French
1 reference
INNOVATE-PCI Investigators
1 reference
29 May 2012
1 reference
1 reference
Identifiers
1 reference